Darolutamide

Treatment intensification with darolutamide plus androgen deprivation therapy and docetaxel improved OS among men with metastatic hormone-sensitive prostate cancer regardless of disease volume or risk, according to study results.

The FDA approved darolutamide tablets in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer.

The FDA granted priority review to darolutamide in combination with docetaxel for treatment of metastatic hormone-sensitive prostate cancer.

Tanya Dorff, MD, section chief of the genitourinary disease program at City of Hope, spoke with Healio about results from the ARASENS trial presented at the 2022 ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — The addition of darolutamide to androgen deprivation therapy and docetaxel prolonged OS among men with metastatic hormone-sensitive prostate cancer, according to study results presented at ASCO Genitourinary Cancers Symposium.

The addition of darolutamide to docetaxel and androgen deprivation therapy significantly prolonged OS among men with metastatic hormone-sensitive prostate cancer, according to topline results of the randomized phase 3 ARASENS trial.

In this video, Eugene Shenderov, MD, PhD, assistant professor of oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, discussed two studies that highlight positive results from darolutamide for prostate cancer.